CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
CRISPR Therapeutics Stock Up 2.0 %
CRSP stock opened at $49.00 on Thursday. The firm has a market capitalization of $4.16 billion, a PE ratio of -18.01 and a beta of 1.68. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The stock has a 50-day simple moving average of $47.14 and a two-hundred day simple moving average of $53.59.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. The company’s revenue was down 99.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.98) EPS. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on CRISPR Therapeutics
Institutional Trading of CRISPR Therapeutics
Large investors have recently modified their holdings of the business. Riggs Asset Managment Co. Inc. boosted its position in shares of CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after acquiring an additional 200 shares during the last quarter. Global Trust Asset Management LLC boosted its position in shares of CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Larson Financial Group LLC lifted its position in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares during the last quarter. NBC Securities Inc. lifted its position in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after buying an additional 438 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its position in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after buying an additional 307 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
- Five stocks we like better than CRISPR Therapeutics
- How to Calculate Options Profits
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Dividend Payout Ratio Calculator
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Using the MarketBeat Stock Split Calculator
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.